Opening up a drug delivery route — Discovery of a new vehicle peptide
Share

IMAGE: This is a cyclic decapeptide, which mimics the dimerization arm of the EGF receptor (EGFR), was previously found to be captured into cells. The authors have found the promising potential… view more 

Credit: Department of Medicinal Chemistry,TMDU

Tokyo Medical and Dental University (TMDU) study identifies promising lead compound for delivery of therapeutically effective peptides

Tokyo – In the field of anticancer therapeutics, cationic antimicrobial peptides (AMPs) have gained prominence because of their cytotoxic and anticancer activity in drug-resistant cancer cells. Peptides are compounds consisting of two or more amino acids linked in a chain.

A membrane impermeable proapoptotic domain (PAD) peptide [KLAKLAK]2 is known to be an antimicrobial agent and to cause mitochondrial membrane disruption, followed by cell death. Most AMPs including PAD have antitumor functions because of a multifunctional host defense system of multicellular organisms; however, they cannot penetrate cell membranes, and alone, they have little cytotoxicity.

Previous studies have shown PAD peptides entering cells by their conjugation with cell-penetrating peptides (CPPs). Particularly, a team of Tokyo Medical and Dental University (TMDU) researchers has shown a cyclic decapeptide, termed peptide 1, mimics the dimerization arm of the EGF receptor (EGFR). EGFR is involved in cellular signal transductions

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD